GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » Asset Turnover

AVANIR Pharmaceuticals (FRA:AV2B) Asset Turnover : 0.16 (As of Sep. 2014)


View and export this data going back to . Start your Free Trial

What is AVANIR Pharmaceuticals Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. AVANIR Pharmaceuticals's Revenue for the three months ended in Sep. 2014 was €25.38 Mil. AVANIR Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2014 was €162.70 Mil. Therefore, AVANIR Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2014 was 0.16.

Asset Turnover is linked to ROE % through Du Pont Formula. AVANIR Pharmaceuticals's annualized ROE % for the quarter that ended in Sep. 2014 was -33.54%. It is also linked to ROA % through Du Pont Formula. AVANIR Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2014 was -26.93%.


AVANIR Pharmaceuticals Asset Turnover Historical Data

The historical data trend for AVANIR Pharmaceuticals's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVANIR Pharmaceuticals Asset Turnover Chart

AVANIR Pharmaceuticals Annual Data
Trend Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.16 0.49 0.91 0.61

AVANIR Pharmaceuticals Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.38 0.37 0.29 0.16

Competitive Comparison of AVANIR Pharmaceuticals's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, AVANIR Pharmaceuticals's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVANIR Pharmaceuticals's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AVANIR Pharmaceuticals's Asset Turnover distribution charts can be found below:

* The bar in red indicates where AVANIR Pharmaceuticals's Asset Turnover falls into.



AVANIR Pharmaceuticals Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

AVANIR Pharmaceuticals's Asset Turnover for the fiscal year that ended in Sep. 2014 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Sep. 2014 )/( (Total Assets (A: Sep. 2013 )+Total Assets (A: Sep. 2014 ))/ count )
=89.263/( (56.907+238.219)/ 2 )
=89.263/147.563
=0.60

AVANIR Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2014 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2014 )/( (Total Assets (Q: Jun. 2014 )+Total Assets (Q: Sep. 2014 ))/ count )
=25.379/( (87.176+238.219)/ 2 )
=25.379/162.6975
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


AVANIR Pharmaceuticals  (FRA:AV2B) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

AVANIR Pharmaceuticals's annulized ROE % for the quarter that ended in Sep. 2014 is

ROE %**(Q: Sep. 2014 )
=Net Income/Total Stockholders Equity
=-43.808/130.626
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-43.808 / 101.516)*(101.516 / 162.6975)*(162.6975/ 130.626)
=Net Margin %*Asset Turnover*Equity Multiplier
=-43.15 %*0.624*1.2455
=ROA %*Equity Multiplier
=-26.93 %*1.2455
=-33.54 %

Note: The Net Income data used here is four times the quarterly (Sep. 2014) net income data. The Revenue data used here is four times the quarterly (Sep. 2014) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

AVANIR Pharmaceuticals's annulized ROA % for the quarter that ended in Sep. 2014 is

ROA %(Q: Sep. 2014 )
=Net Income/Total Assets
=-43.808/162.6975
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-43.808 / 101.516)*(101.516 / 162.6975)
=Net Margin %*Asset Turnover
=-43.15 %*0.624
=-26.93 %

Note: The Net Income data used here is four times the quarterly (Sep. 2014) net income data. The Revenue data used here is four times the quarterly (Sep. 2014) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


AVANIR Pharmaceuticals Asset Turnover Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


AVANIR Pharmaceuticals (FRA:AV2B) Business Description

Traded in Other Exchanges
N/A
Address
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

AVANIR Pharmaceuticals (FRA:AV2B) Headlines

No Headlines